Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...
22h
Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...
Though Tesla’s shares doubled over the past 12 months, they’ve had a tough run since the inauguration. Investors are waiting ...
The maker of Yankee Candle and Sharpie pens said volumes fell and foreign exchange rates were a headwind in the fourth quarter.
The post contains 50 new customer stories, which appear at the beginning of each section of customer lists. The post will be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback